Ted Slocomb

Mr. Slocomb has served as Vice President, Commercial Planning since January 2015. He has over 22 years of experience in the areas of new product and portfolio planning, marketing, corporate development and venture capital in the biotechnology and pharmaceutical industries, including significant experience developing and executing commercialization strategies for biopharmaceuticals in rare diseases. Before joining Audentes, Mr. Slocomb was Senior Director, Corporate Development for Fate Therapeutics, which is developing stem cell therapies for rare hematologic and muscle disorders. Mr. Slocomb also spent over seven years at Amylin Pharmaceuticals, Inc. in new product commercialization leadership roles, including leading the creation and execution of the commercialization strategy for MYALEPT® (metreleptin for injection) for rare lipodystrophy.

Prior to his position at Amylin, Mr. Slocomb held roles of increasing responsibility in healthcare strategy consulting, strategic planning and marketing in the pharmaceutical industry and as the Principal of a healthcare venture capital fund.

Mr. Slocomb earned a B.A. in Genetics from the University of California, Berkeley and a M.B.A. from the Leonard N. Stern School of Business at New York University, where he was a Stern Scholar.

Ted Slocomb is the Vice President, Global Market Access - Gene Therapy at Audentes Therapeutics, based in United States, North America. With a background in Biotechnology, Ted Slocomb has a rich history of leadership and innovation.Ted Slocomb studied BA Genetics at University of California Berkeley. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.